Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 612 across all filing types
Latest filing 2022-03-22 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Issue and repurchase of series C shares for performance-based share saving program
Share Issue/Capital Change Classification · 1% confidence The document explicitly details the 'Issue and repurchase of series C shares for performance-based share saving program'. This action involves the company resolving on a directed issue and immediate repurchase of shares, which directly relates to changes in the company's capital structure and share count. This aligns precisely with the definition of 'Share Issue/Capital Change' (SHA). It is not a general financing update (CAP), nor is it a director's dealing (DIRS) or a transaction in own shares (POS), as it describes a specific program-related issuance/repurchase mechanism tied to performance shares, which falls under capital structure management.
2022-03-22 English
Annual Report (ESEF) 2021
Annual Report (ESEF) Classification · 1% confidence FY 2021
2022-03-22 Swedish
Annual Report (ESEF) 2021
Annual Report (ESEF) Classification · 1% confidence FY 2021
2022-03-22 Swedish
Valberedningens förslag till styrelse inför årsstämman 2022 i Alligator Bioscience AB
AGM Information Classification · 1% confidence The document is titled 'Valberedningens förslag till styrelse inför årsstämman 2022 i Alligator Bioscience AB' (Nomination Committee's proposal for the Board of Directors ahead of the 2022 Annual General Meeting). It details the committee's proposals regarding the composition of the board, including re-elections and new nominations, along with biographies and shareholdings of the proposed members. This content directly relates to the preparation and proposals for the Annual General Meeting (AGM). While it is a proposal *for* the AGM, it is not the final voting result (DVA) nor is it the proxy solicitation material (PSI). It is a specific announcement concerning the governance structure leading up to the AGM. Given the options, 'AGM Information' (AGM-R) is the most appropriate classification for materials detailing board nominations presented by the Nomination Committee for the upcoming AGM.
2022-03-11 Swedish
The Nomination Committee’s proposal regarding the Board of Directors ahead of the Annual General Meeting 2022 in Alligator Bioscience AB
Board/Management Information Classification · 1% confidence The document explicitly discusses the 'Nomination Committee's proposal regarding the Board of Directors ahead of the Annual General Meeting 2022'. It details proposed re-elections and new elections for Board members, including biographical information and shareholdings related to the nominees. This content directly relates to the governance and composition of the board, which is a key component of materials presented or discussed during an Annual General Meeting (AGM). While it is an announcement *before* the AGM, the subject matter (Board nominations for the AGM) aligns most closely with AGM-related materials, specifically the proposals that would be voted upon. It is not a general management change (MANG) as it is tied specifically to the AGM vote, nor is it a proxy statement (PSI) which typically solicits votes for a broader set of items. Therefore, AGM-R is the most appropriate classification for pre-AGM nomination proposals.
2022-03-11 English
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding and voting rights for a specific holder ('Allegro Investment Funt, L.P.') in the issuer ('Alligator Bioscience AB'). It explicitly shows 'Before the transaction' and 'After the transaction' figures for shares and voting rights, culminating in a new percentage holding (25.22525%). This structure is characteristic of a notification regarding changes in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific disclosure about ownership thresholds being crossed or changed.
2022-03-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.